Amgen Inc.

Jerry D. Choate retired from Allstate Corporation, an insurance company, at the end of 1998 where he had served as Chairman of the Board and Chief Executive Officer since 1995. Mr. Choate also serves as a director of Amgen, Inc. and Van Kampen Mutual Funds. He has served as a director of Valero since 1999.

Frank J. Biondi, Jr., 63, Senior Managing Director, WaterView Advisors LLC (private equity fund specializing in media) since 1999. Director of Amgen, Inc., Cablevision Systems Corporation, The Bank of New York Mellon and Seagate Technology. (Biographical Information as of April 9, 2008)

Mark McCamish, M.D., Ph.D., Senior Vice President and Chief Medical Officer, joined the Company in February 2007. From 2003 to February 2007, Dr. McCamish served as Chief Medical Officer and Vice President of Clinical Development for Perlegen Sciences, Inc., a company that analyzes unique genetic variations in clinical trial participants to develop genetically targeted, late-stage therapeutics and diagnostics. Between January 1998 and September 2003, Dr. McCamish served at Amgen, Inc., most recently as Global Development Leader responsible for the clinical development of Amgen's Aranesp product in new indications. From 1990 to 1997, he worked as a director at Abbott Laboratories with broad responsibilities that included national and international clinical research, design and development of new products in various therapeutic areas. Dr. McCamish received his Ph.D. at Penn State University, his M.D. from the University of California, Los Angeles, and bachelor's and master's degrees from the University of California, Santa Barbara . Dr. McCamish is Board Certified in Internal Medicine and Nutrition & Metabolism.

Kevin Sharer has been Amgen's chief executive officer and president since May 2000, and he has also been chairman of the company's Board of Directors since January 2001. From October 1992 to May 2000, Sharer was Amgen's president and chief operating officer. He has been a director of Amgen since November 1992. Before joining Amgen, Sharer was president of the Business Markets Division of MCI Communications. Prior to MCI, Sharer served in a variety of executive capacities at General Electric and was a consultant for McKinsey & Company. Sharer serves on the Board of Directors of Northrop Grumman Corporation and Chevron.

Robert Bradway became executive vice president and chief financial officer for Amgen in April 2007. He joined the company in 2006 as vice president, Operations Strategy. Prior to joining Amgen, Bradway spent 18 years at Morgan Stanley in New York and London, where he was a managing director in investment banking. He led Morgan Stanley's healthcare practice in Europe for several years and also ran the company's European banking department. Bradway holds a BA in Biology from Amherst College and an MBA from Harvard University.

Tom Flanagan became senior vice president and CIO in September 2006. Prior to that, he led Amgen's Global ERP program since February 2005. He joined Amgen in June 2004 as vice president, Information Systems. Prior to joining Amgen, Flanagan spent eight years at MCI, where he served in a variety of executive capacities, including CIO and senior vice president of Global Service Delivery. Before joining MCI in December 1995, Flanagan spent 24 years as an officer in the United States Navy. Flanagan is a graduate of the U.S. Naval Academy, MIT, U.S. Naval War College, and Harvard University’s John F. Kennedy School of Government.

George J. Morrow has served as a director of Align since February 2006. He is currently the Executive Vice President, Global Commercial Operations at Amgen Inc., a global biotechnology company, where he also served as Executive Vice President of Worldwide Sales and Marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. Mr. Morrow holds a B.S. in chemistry from Southampton College, Long Island University, an M.S. in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.

Dr. Perlmutter is Executive Vice President for Research and Development at Amgen. A graduate of Reed College (Portland, Oregon), Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University (St. Louis) in 1979. Thereafter he pursued clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco. From 1981 to 1984 he was a Lecturer in the Division of Biology at the California Institute of Technology. He joined the Departments of Medicine and Biochemistry and the Howard Hughes Medical Institute at the University of Washington (Seattle) in 1984, and in 1989 became Professor and founding Chairman of the Department of Immunology there. During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. In 1997 he left the University of Washington to join Merck and Co., ultimately rising to the rank of Executive Vice President, Worldwide Basic and Preclinical Research. He left Merck in 2001 to join Amgen in California. Dr. Perlmutter is also a director of Stem Cells, Inc., a Trustee of Reed College, and Chairman of the Board of Directors of the Institute for Systems Biology, a not-for-profit research institute based in Seattle, Washington. He was previously President of the American Association of Immunologists, and is a Fellow of the American Academy of Arts and Sciences.

As senior vice president and chief compliance officer, Anna Richo oversees Amgen’s compliance program, which promotes ethical business conduct throughout the organization and touches on all company activities related to product development, manufacturing, marketing and reporting. Richo joined Amgen in 2003 as vice president, Law. Previously, she spent 12 years at Baxter Healthcare Corporation in roles of increasing responsibility in law and compliance, including vice president, Law, for their Bioscience Division. Additionally, for more than five years she served on the Board of Directors of Cytyc Corporation and was a member of the Audit and Finance Committees. Richo received her Juris Doctor degree from DePaul University College of Law and her Bachelor of Science in Industrial and Labor Relations from Cornell University. She co-chairs the Straus Institute Council of Distinguished Advisors at Pepperdine University’s School of Law.

Brian McNamee joined Amgen as senior vice president, Human Resources in June 2001. Before joining Amgen, McNamee was vice president of Human Resources at Dell Computers in Austin, Texas. He has held a variety of international executive positions at General Electric over a 12-year period, and he also served as senior vice president for the West Coast division of NBC in Burbank, California. McNamee received his bachelor's degree in journalism from St. Bonaventure University and received his master's degree in industrial and labor relations from Cornell University in 1987.

David Scott became senior vice president, general counsel and secretary in March 2004. From May 1999 to February 2004, Scott served as senior vice president and general counsel of Medtronic, Inc., a medical technology company, and also as secretary from January 2000. From December 1997 to April 1999, Scott served as general counsel of London-based United Distillers & Vintners. From April 1996 to November 1997, Scott served as general counsel of London-based International Distillers & Vintners.

Dr. Fabrizio Bonanni is Amgen's executive vice president, Operations, overseeing the company's global production activities as well as site and facilities management. Since joining Amgen in April 1999, Bonanni has served as senior vice president, Manufacturing; senior vice president, Quality and Compliance; and corporate compliance officer. Previously, he was corporate vice president, Regulatory and Clinical Affairs and corporate vice president, Quality System for Baxter International Inc., a company he joined in 1974. At Baxter, Bonanni spent half of his career in international operations, including an eight-year assignment as vice president, Quality and Regulatory Affairs, at the company's European headquarters in Brussels, Belgium. His responsibilities at Baxter included quality and regulatory affairs, manufacturing, microbiology and sterilization engineering, and total quality management, for (bio)pharmaceuticals, blood derivatives, medical devices and in-vitro diagnostics. Bonanni earned his doctorate in chemistry, magna cum laude, from the University of Florence and has done postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is a state-certified chemist and a member of the Ordine dei Chimici of Tuscany. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management, and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. Bonanni is fluent in French and English, in addition to his native Florentine Italian. Bonanni serves on the Board of Trustees for the Museum of Contemporary Art in Los Angeles. He also serves as a Trustee of the Science Technology and Research Trust of Puerto Rico.

Since May 2005, Cynthia Schwalm has been Amgen's vice president and general manager of the Oncology Business Unit. She oversees sales, marketing, access and reimbursement, advocacy and new product launch teams for Amgen's oncology business in the United States. From May of 2003 to May of 2005, Schwalm served as senior director of Marketing in Oncology. Before joining Amgen, Schwalm was managing director of Ortho Biotech, Johnson & Johnson's Biotechnology commercial operations unit in the U.K. and Ireland. Previous to this role, Schwalm was Executive Director of J&J Pharma's Global Franchise Development for the Analgesia and Women's Health Franchises. Schwalm held various sales and marketing positions in J&J from 1984 until joining Amgen. She holds a master's degree in business administration from the Wharton School of Business, and is a member of the Healthcare Business Women's Association.

Dr. David Lacey is vice president, Research and Amgen South San Francisco Site Leader. Lacey joined Amgen in 1994 as associate medical director, Department of Experimental Pathology and has held several positions of increasing responsibility over the past 12 years. Prior to joining Amgen, Lacey was assistant professor of Pathology at Jewish Hospital, Washington University Medical Center. Lacey received a B.S. and M.D. from the University of Colorado.

Helen Torley has been vice president, and general manager of the Nephrology Business Unit since October of 2003. Torley joined Amgen in June of 2002 in the role of therapeutic area head, Inflammation Global Marketing. She began her industry career at Sandoz/Novartis in 1990, heading up the clinical development program for Sandimmune in rheumatoid arthritis. During her 7 years at Novartis, Torley held positions of increasing responsibility in medical marketing and marketing, ultimately serving as vice president of Medical Affairs, with responsibility for medical marketing and phase IIIB/IV trials across all therapeutic areas. In 1997, Torley joined Bristol Myers Squibb and held various positions, including RVP cardiovascular and metabolic sales, heading up the 150 sales representatives from the California sales team. Prior to coming to the United States, she was senior registrar in rheumatology at the Royal Infirmary, Glasgow, Scotland. Torley received her MBChB in 1984 from the University of Glasgow and her MRCP in 1987.

Dr. Nahed Ahmed is vice president, Project Planning and Management for Research and Development. Prior to joining Amgen, Ahmed held several positions at Aventis Pharmaceuticals from 1993 to 1999, including senior vice president of Global Productivity, Portfolio, and Project Management (PPPM). Ahmed is recognized in Who's Who in Frontier Science and Technology, Personalities of America, International Directory of Distinguished Leadership, and Empire Who's Who Registry of Executives and Professionals. She was selected as a recipient of the YWCA TWIN (Tribute to Women in Industry) Award. Ahmed was selected in 2004 as an honorary foreign member of the Beijing Municipal Government and awarded an honorary professorship at Peking Union Medical College. Additionally, she serves on the Board of Directors of Chronogen Inc.

Mark de Souza is Senior Director of Corporate Development at Dyax Corp. Since 2001, his primary focus is partnering Dyax?s phage display technology for the discovery and development of biopharmaceuticals from Dyax?s antibody, peptide, and protein libraries. He is responsible for initiating new collaborations, in-licensing new technology, marketing Dyax?s scientific and business achievements, and managing existing alliances. Dyax currently has over 75 licensees and collaborators, including Amgen, AstraZeneca, Baxter, Biogen Idec, Genzyme, ImClone Systems, MedImmune, and Tanox.

Jim has more than 22 years experience as both consultant and company insider at more than 133 U.S. companies, from smaller regional firms to divisions of several Fortune 500 companies, including Kal Kan, Amgen, Litton, Kraft Foods, Abbott Laboratories, Dannon Yogurt, Timex, Tenet Healthcare and others. Jim is a specialist at market introductions, and managing execution of complex, strategic business initiatives in Marketing, Operations, Business Structure, Technology Development, Sales Force Structure, Sales Management, Distribution Channels Development, inter-departmental alignment and post-merger integration. His results have included turnarounds at divisions of Litton and Gannett, aggressive expansions at Kenco Construction (growth from $2MM to $32MM revenues in 3 years); and Accele Electronics (growth from $8MM to $20MM revenues in 3 years); operations restructures from the western division of Kal Kan (division of M&M Mars) to BestForms (who became the highest quality mid-run forms printer in the US) and OneCentral Bank (who became the best managed mid-size bank in California). Jim also has extensive background in Advertising, Engineering, IS / IT Management, Mass Production, Territory and Sales Management, Recruiting, Training, Turnaround Management and Business Development.

Mr. Johnson has a proven track record with more than 20 years of healthcare experience in marketing and general management with professional service companies providing consultation to leading corporations including Abbott, Amgen, Baxter, Beckman Coulter, Biogen Idec, Guidant, Johnson & Johnson, 3M Healthcare and emerging companies. Mr. Johnson has supported the launch of more than 200 global brands. He has a BBA in marketing from the University of Texas and an MBA in finance from Michigan State University.